Watch for CarefulInvestor to be posting diarrhea of the mouth as he is #$%$ his pants as it appears accelerated approval of Eteplirsen appears imminent.
It is true they haven't hit a home run in a while, yet they still brought in $258M in revenue in the last 12 months. Can you imagine what the revenue explosion will look like when they DO hit a home run? :-)
I've stopped adding money into the corrupt stock market. Stockpiling cash.
Why are you such a #$%$? Be glad the internet affords you complete anonymity to run your mouth. In a room full of investors you would be absolutely silent. You wouldn't be spreading your lies.
Spikes up on news of a secondary, down 7% today without any news ... #$%$.
This market is so corrupt and manipulated it is a joke. More money avoids this corruption daily.
Wrong. ALL the kids on Etep are still alive AND still walking.
This will be a defining moment for the FDA as well as for Sarepta.
The FDA is SO far off course it is unthinkable.
How did we end up with such a messed up FDA?
Nobody from the FDA is accountable for any. Ever. We need only look at the current state of Eteplirsen at the FDA to see that.
Word may leak out early about the pending approval by the FDA. If so, the run up will be fast and furious.
Um, perhaps you didn't know this, but Romney isn't running ...
But since you hate Romney and Romney is against Trump, does that mean you are FOR Trump?
What a kook.
And by "Chronic insider selling" you are referring to the standard executive options exercised and then sold as part of their pay package, which is the EXACT SAME for almost all publicly held companies out there. And the total number of shares held by insiders is the EXACT SAME percentage as it was two years ago, making it clear you don't understand any of what you are claiming.
So a month later, now what do you think? While I agree that it was a large trial, etc., you simply cannot overcome the corruption of the FDA.
Honestly, not enough information yet to know for sure, but I have to think that if there was a RTF it was because there was some missing component or somehow the application wasn't aligned with how the FDA wants to see it.
If I had to guess, they will correct the application and re-file it by the end of March (if I were CEO this would be my plan). This would give them enough time to remedy the situation and still respond quickly to the change. In theory, this could be a blessing in disguise as it would let them fix anything wrong and increase their chance for approval. It also could distance them from SRPT and BMRNs failures with the FDA and give the FDA a chance to show a victory in this DMD space by approving Translarna/Ataluren. While I don't like the RTF, it is what it is, and could end up being a workable solution.
From the downside, if there was some material deficiency in the filing that triggered additional clinical trials, that would be disastrous. I don't think that is the case here though because this is a lot like filing your income taxes - if you don't have your SS# listed in the right box, you can't file. It isn't that there is anything wrong with your return, but that you didn't have the forms properly filled out. Let's hope that is the case here. If that proves true (that it is just a filing alignment) then this could be a sharp rebound and all bets are back on. Only time will tell.